DRIZALMA SPRINKLE (duloxetine) by Fosun Pharma is antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the cns. First approved in 2019.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
DRIZALMA SPRINKLE is a delayed-release oral capsule formulation of duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) approved in 2019. It works by potentiating serotonergic and noradrenergic activity in the CNS to produce antidepressant, central pain inhibitory, and anxiolytic effects. The sprinkle formulation allows flexible dosing by opening the capsule and sprinkling pellets on food.
Early peak-stage product with minimal Part D penetration (~35 claims in 2023) suggests opportunity to expand market adoption through commercial team growth.
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta
A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Worked on DRIZALMA SPRINKLE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moDRIZALMA SPRINKLE positions you in a peak-stage specialty formulation asset with a supportive patent wall through 2037, but limited current commercial scale (35 Part D claims in 2023). Working on this product offers stability in a growing psychiatric/pain management portfolio under Fosun Pharma, with career progression tied to market share expansion and market education initiatives.